Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.

Heine S, Kleih M, Giménez N, Böpple K, Ott G, Colomer D, Aulitzky WE, van der Kuip H, Silkenstedt E.

J Hematol Oncol. 2018 Sep 4;11(1):112. doi: 10.1186/s13045-018-0657-6.

2.

Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.

Arandkar S, Furth N, Elisha Y, Nataraj NB, van der Kuip H, Yarden Y, Aulitzky W, Ulitsky I, Geiger B, Oren M.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6410-6415. doi: 10.1073/pnas.1719076115. Epub 2018 Jun 4.

3.

Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project.

de Hoogt R, Estrada MF, Vidic S, Davies EJ, Osswald A, Barbier M, Santo VE, Gjerde K, van Zoggel HJAA, Blom S, Dong M, Närhi K, Boghaert E, Brito C, Chong Y, Sommergruber W, van der Kuip H, van Weerden WM, Verschuren EW, Hickman J, Graeser R.

Sci Data. 2017 Nov 21;4:170170. doi: 10.1038/sdata.2017.170.

4.

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

Höring E, Montraveta A, Heine S, Kleih M, Schaaf L, Vöhringer MC, Esteve-Arenys A, Roué G, Colomer D, Campo E, Ott G, Aulitzky WE, van der Kuip H.

Br J Haematol. 2017 May;177(4):557-561. doi: 10.1111/bjh.14571. Epub 2017 Mar 14.

PMID:
28295185
5.

An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis.

Staiger AM, Duppel J, Dengler MA, van der Kuip H, Vöhringer MC, Aulitzky WE, Rosenwald A, Ott G, Horn H.

Leuk Lymphoma. 2017 Aug;58(8):1922-1930. doi: 10.1080/10428194.2016.1263841. Epub 2016 Dec 6.

PMID:
27919179
6.

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes.

Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.

Sci Rep. 2016 Jul 20;6:29930. doi: 10.1038/srep29930.

7.

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, Sauer G, Aulitzky WE, van der Kuip H.

Cancer Res. 2016 May 15;76(10):2868-75. doi: 10.1158/0008-5472.CAN-15-2908. Epub 2016 Mar 24.

8.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

9.

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj A, Metsalu T, Oswald E, Erkens-Schulze S, Delgado San Martin JA, Turkki R, Wedge SR, af Hällström TM, Schueler J, van Weerden WM, Verschuren EW, Barry ST, van der Kuip H, Hickman JA.

Sci Rep. 2015 Dec 9;5:17187. doi: 10.1038/srep17187.

10.

A Temperature of 40 °C Appears to be a Critical Threshold for Potentiating Cytotoxic Chemotherapy In Vitro and in Peritoneal Carcinomatosis Patients Undergoing HIPEC.

Schaaf L, van der Kuip H, Zopf W, Winter S, Münch M, Mürdter TE, Thon KP, Steurer W, Aulitzky WE, Ulmer C.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S758-65. doi: 10.1245/s10434-015-4853-0. Epub 2015 Sep 8.

PMID:
26350370
11.

High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.

Rudisch A, Dewhurst MR, Horga LG, Kramer N, Harrer N, Dong M, van der Kuip H, Wernitznig A, Bernthaler A, Dolznig H, Sommergruber W.

PLoS One. 2015 Apr 28;10(4):e0124283. doi: 10.1371/journal.pone.0124283. eCollection 2015.

12.

Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo.

Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H; IMI PREDECT Consortium.

Biotechnol J. 2014 Sep;9(9):1115-28. doi: 10.1002/biot.201300492. Review.

PMID:
25174503
13.

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.

Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H.

Cell Death Dis. 2014 Jul 10;5:e1318. doi: 10.1038/cddis.2014.284.

14.

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vöhringer MC, Horn H, Ott G, Aulitzky WE, van der Kuip H.

Cell Death Dis. 2014 Jan 23;5:e1013. doi: 10.1038/cddis.2013.552.

15.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

16.

Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, van der Kuip H.

Cancer Res. 2013 Mar 1;73(5):1460-9. doi: 10.1158/0008-5472.CAN-12-2876. Epub 2013 Jan 9.

17.

Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach.

Yilmaz A, Dengler MA, van der Kuip H, Yildiz H, Rösch S, Klumpp S, Klingel K, Kandolf R, Helluy X, Hiller KH, Jakob PM, Sechtem U.

Eur Heart J. 2013 Feb;34(6):462-75. doi: 10.1093/eurheartj/ehs366. Epub 2012 Oct 26.

PMID:
23103659
18.

Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.

Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A, Ott G, Mürdter TE, Oren M, Aulitzky WE, van der Kuip H.

Cancer Res. 2012 Nov 15;72(22):5824-32. doi: 10.1158/0008-5472.CAN-12-1201. Epub 2012 Sep 7.

19.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T.

Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12.

20.

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.

Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M.

Genome Med. 2011 Dec 23;3(12):82. doi: 10.1186/gm298.

21.

Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.

Dengler MA, Staiger AM, Gutekunst M, Hofmann U, Doszczak M, Scheurich P, Schwab M, Aulitzky WE, van der Kuip H.

PLoS One. 2011;6(9):e25139. doi: 10.1371/journal.pone.0025139. Epub 2011 Sep 20.

22.

p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.

Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE, van der Kuip H.

PLoS One. 2011 Apr 21;6(4):e19198. doi: 10.1371/journal.pone.0019198.

23.

Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.

Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE.

Mol Cancer. 2010 Jun 27;9:168. doi: 10.1186/1476-4598-9-168.

24.

Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.

Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.

Cancer Res. 2009 Dec 15;69(24):9337-45. doi: 10.1158/0008-5472.CAN-09-0548.

25.

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.

26.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Henkes M, van der Kuip H, Aulitzky WE.

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

27.

Estrogen-mediated downregulation of CD24 in breast cancer cells.

Kaipparettu BA, Malik S, Konduri SD, Liu W, Rokavec M, van der Kuip H, Hoppe R, Hammerich-Hille S, Fritz P, Schroth W, Abele I, Das GM, Oesterreich S, Brauch H.

Int J Cancer. 2008 Jul 1;123(1):66-72. doi: 10.1002/ijc.23480. Erratum in: Int J Cancer. 2019 Nov 15;145(10):E21.

28.

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.

Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H.

Oncogene. 2008 Jul 17;27(31):4380-4. doi: 10.1038/onc.2008.68. Epub 2008 Mar 24.

PMID:
18362889
29.

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S.

Clin Cancer Res. 2007 Jun 1;13(11):3198-206.

30.

Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.

van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE.

BMC Cancer. 2006 Apr 7;6:86.

31.

The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.

Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, Stülten C, van der Kuip H, Pauli-Magnus C, Raub U, Kuhlmann U, Mettang T.

Nephrol Dial Transplant. 2006 Mar;21(3):749-55. Epub 2005 Oct 25.

PMID:
16249205
32.

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.

Fritz P, Cabrera CM, Dippon J, Gerteis A, Simon W, Aulitzky WE, van der Kuip H.

Breast Cancer Res. 2005;7(3):R374-84. Epub 2005 Mar 21.

33.

Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.

Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brümmendorf TH.

Exp Hematol. 2005 May;33(5):542-9.

PMID:
15850831
34.

Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.

Moehring A, Wohlbold L, Aulitzky WE, van der Kuip H.

Cell Death Differ. 2005 Jun;12(6):627-36.

35.

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.

van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE.

Am J Pharmacogenomics. 2005;5(2):101-12. Review.

PMID:
15813673
36.

All common p210 and p190 Bcr-abl variants can be targeted by RNA interference.

Wohlbold L, van der Kuip H, Moehring A, Granot G, Oren M, Vornlocher HP, Aulitzky WE.

Leukemia. 2005 Feb;19(2):290-2. No abstract available.

PMID:
15565163
37.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.

Blood. 2005 Feb 15;105(4):1652-9. Epub 2004 Sep 30.

PMID:
15459011
38.

Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.

van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE.

Leuk Res. 2004 Apr;28(4):405-8.

PMID:
15109541
39.

Apoptosis of mesothelial cells caused by unphysiological characteristics of peritoneal dialysis fluids.

Alscher DM, Biegger D, Mettang T, van der Kuip H, Kuhlmann U, Fritz P.

Artif Organs. 2003 Nov;27(11):1035-40.

PMID:
14616522
40.

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE.

Blood. 2003 Sep 15;102(6):2236-9. Epub 2003 May 15.

PMID:
12750174
41.

Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters.

Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, Von Richter O, Griese EU, Eichelbaum M, Fromm MF.

Clin Pharmacol Ther. 2002 Mar;71(3):131-40.

PMID:
11907487
42.

Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.

Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE.

Cancer Res. 2001 Oct 15;61(20):7635-41.

43.

Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.

van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE.

Blood. 2001 Sep 1;98(5):1532-41.

PMID:
11520804
44.

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.

Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF.

Pharmacogenetics. 2001 Jun;11(4):293-8.

PMID:
11434506
45.

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.

Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE.

Blood. 2000 Sep 1;96(5):1933-9.

PMID:
10961897
46.

The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.

Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE.

Clin Cancer Res. 2000 May;6(5):1958-68.

47.

The DNA-binding subunit p140 of replication factor C is upregulated in cycling cells and associates with G1 phase cell cycle regulatory proteins.

van der Kuip H, Carius B, Haque SJ, Williams BR, Huber C, Fischer T.

J Mol Med (Berl). 1999 Apr;77(4):386-92.

PMID:
10353443
48.

Induction of the pro-myelocytic leukaemia gene by type I and type II interferons.

Heuser M, van der Kuip H, Falini B, Peschel C, Huber C, Fischer T.

Mediators Inflamm. 1998;7(5):319-25.

49.

Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.

Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, Aulitzky WE.

Br J Haematol. 1998 Feb;100(2):295-303.

PMID:
9488616
50.

Overexpression of mouse p140 subunit of replication factor C accelerates cellular proliferation.

Jaharul Haque S, van der Kuip H, Kumar A, Aulitzky WE, Rutherford MN, Huber C, Fischer T, Williams BR.

Cell Growth Differ. 1996 Mar;7(3):319-26.

Supplemental Content

Loading ...
Support Center